143582-95-0

Upstream product

• 143582-97-2 1-benzyloxy-4-[difluoro(methylthio)methoxy]benzene 
• 828-27-3 4-Trifluoromethoxyphenol 
• 103-16-2 4-Benzyloxyphenol 
• 200956-13-4 2-Bromo-4-(trifluoromethoxy)phenol 
• 100-39-0 benzyl bromide 
• 143582-90-5 O-4-benzyloxyphenyl S-methyl dithiocarbonate 

Downstream Products

• 200953-37-3 (5R,6S)-3-(2-benzyloxy-5-(trifluorometoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)azaspiro[4.5]dec-3-ene 

Relevant academic research and scientific papers

Use of NK-1 receptor antagonists for treating major depressive disorders

The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor

Stereocontrolled syntheses of epimeric 3-aryl-6-phenyl-1-oxa-7-azaspiro[4.5]decane NK-1 receptor antagonist precursors

Equation presented Complementary stereoselective syntheses of individual C3 epimers of the NK-1 receptor antagonist precursor 1 have been developed. Both diastereomers were derived from the common intermediate 3; introduction of the 3S stereocenter in 1a

A convenient synthesis of trifluoromethyl ethers by oxidative desulfurization-fluorination of dithiocarbonates

Trifluoromethyl ethers R-OCF3 are easily synthesized from the corresponding dithiocarbonates R-OCS2Me (R = aryl or primary alkyl) by a reagent system consisting of 70% HF/pyridine and an N-halo imide. When the reaction is applied to R-OCS2Me wherein R = secondary alkyl, tertiary alkyl, or benzylic group, fluorination leading to the corresponding alkyl fluorides R-F is achieved, whereas a combination of 50% HF/pyridine and N- bromosuccinimide affords the corresponding trifluoromethyl ethers R-OCF3 (R = secondary).

Use of NK-1 receptor antagonists for treating stress disorders

The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of stress disorders without concomitant the

USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING BIPOLAR DISORDERS

The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-

Oxidative desulfurization-fluorination of xanthates. A convenient synthesis of trifluoromethyl ethers and difluoro (methylthio)methyl ethers

Treatment of xanthates R-OC(S)SMe with (HF)9/Py and 1,3-dibromo-5,5-dimethylhydantoin gives trifluoromethyl ethers R-OCF3 through intermediates R-OCF2SMe, which could be isolated upon treatment of xanthates with n-Bu4N+H2F3- and N-bromosuccinimide.